Ganetespib (STA-9090) Monotherapy in Untreated Metastatic HER2+/TNBC
Research type
Research Study
Full title
An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy In Women With Previously Untreated Metastic HER2 Positive Or Triple Negative Breast Cancer
IRAS ID
100335
Contact name
David Cameron
Contact email
Sponsor organisation
Synta Pharmaceuticals Corp.
Eudract number
2012-000558-71
Clinicaltrials.gov Identifier
Research summary
This study aims to investigate ganetespib (STA-9090) as a potential new anti-cancer therapy. Ganetespib is a small chemical that binds to, and inhibits a protein called Hsp90. Hsp90 is essential to the activity of certain other proteins (called growth factors) that drive the growth, proliferation, and survival of different types of cancer cells. By inhibiting Hsp90, ganetespib causes the degradation of these downstream growth factors, resulting in the subsequent degradation of cancer cells dependent upon these growth factors. This study aims to evaluate the effectiveness of ganetespib, as a 2nd line treatment, in women with either metastatic HER2 positive, or Triple Negative Breast Cancer (TNBC); patients with these breast cancer subtypes have poor prognosis??s in comparison to patients with other breast cancer subtypes. In clinical trials to date, researchers have seen encouraging preliminary laboratory research of ganetespib treatment for these indications. Results from this study will be used to guide the further development of ganetespib therapy in metastatic breast cancer.
REC name
West of Scotland REC 1
REC reference
12/WS/0117
Date of REC Opinion
25 Jul 2012
REC opinion
Further Information Favourable Opinion